Address: Av. Nações Unidas, 22215 – Alto de Pinheiros São Paulo, 04795-100
,Brazil
Tel: +55 11 5090.8487
Web: http://www.eurofarma.com.br/
In 1972, Eurofarma started its path manufacturing drugs to third parties, national and international laboratories. As the years went by and with the increase of market perception, production capacity, equipment technology and the strict quality control adopted, the company grew. It acquired new companies and started to manufacture and market its own brands and under multinational license.
It is currently the third greatest national capital
pharmaceutical group in Brazil and, according to Grupemef (Group of Pharmaceutical Industry Executive Professionals),
it is one of the five greatest pharmaceutical laboratories in the country. It produces and markets drugs for human and veterinary use, by means of eight business divisions: Pharma (Medical Prescription), Hospital, Generic Drugs, Oncology, Pearson (Veterinary), Third Parties, Export, and Euroglass. Thus, it has a complete line of products which cover several pathologies, acting both in the fight and prevention against various diseases.
The year 2008 was decisive to Eurofarma’s evolution. We were able to maintain our essence, based on ethics, hard work and our product’s quality. At the same time, we made progress on strategic issues, developing actions and establishing partnerships that bring us closer to our Vision.
We commenced the development of clinical trials in this Country for innovative drugs in the Oncology field, being pioneers in the participation of a national industry in a worldwide partnership.
Also in 2008 we opened the Hormones Block in Itapevi Complex. Close to the conclusion of the construction, the following steps are: to open the Oncology and Solid Blocks (the last one being the main Block of the complex) in 2009 and the Injectable Block in 2010. After this process we will centralize the main productive activities of this company in only one place, which provides the proper infra-structure in order to meet the needs of the internal market and to go on with the internationalization project.
Innovative prescription, branded generics, and generics
Maria del Pilar Muñoz, vice-president in charge of M&A and Sustainability at Eurofarma, one of the largest and most innovative pharmaceutical companies in Brazil with operations in 20 countries across…
Eurofarma entered the Peruvian market in 2013 through the acquisition of local player Refasa-Carrión. Rómulo García, the affiliate’s ambitious general manager, discusses the merge and his quest to become a…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
An overview of some of the biggest stories from Latin American pharma and healthcare, including Brazil’s rollout of dengue vaccines following a sharp increase in cases; the Brazilian regulatory agency…
A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards…
Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines…
The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light…
A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s…
The DIA Global Annual Meeting 2023 hosted DIA’s first regulatory Town Hall fully dedicated to one regulator from Latin America, as leadership from Brazil’s Health Regulatory Agency, ANVISA, shared updates on the…
The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on…
A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences…
Having spent 25 years in the rare disease arena, Maria Gabriella Pittis now finds herself at the forefront of a different field, spearheading the launch of Takeda’s dengue vaccine across…
As the COVID-19 pandemic showed, vaccines are humanity’s best weapon in the fight against infectious diseases. Nowhere is this more evident than Latin America, where specific climatic, geographic, and social…
Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts,…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
See our Cookie Privacy Policy Here
